Nano cap Biocept (BIOC +19.4%) is up on more than double normal volume in early trade in response to its announcement that its Target Selector liquid biopsy tests can now be used to assess the presence of circulating tumor cells and biomarkers in the cerebrospinal fluid of breast or lung cancer patients suspected of brain or central nervous system metastases.
Liquid biopsy tests are typically performed with peripheral blood samples.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.